June, '00 | Briefing | Mail | Don't Say This | Articles | Other Places | Archives | Send Mail | Ed Dewke | Legal Stuff | Order | Search | PsorHeads

Initial Report from Canadian Drug Study Subject
M from Canada

Hi Ed. I have had psoriasis for almost 26 years. I really like your site and look forward to the monthly updates. The reason I am writing is because I am currently on a clinical trial.

This trial is a randomized double-blind comparison of LFA3TIP vs. placebo via intravenous. It is

(a) two treatment courses of LFA3TIP with 12 weekly doses per course, or

(b) LFA3TIP for 12 weeks followed by placebo for 12 weeks, or

(c) placebo for 12 weeks followed by LFA3TIP for 12 weeks.

I am on my 10th week and so far I have not noticed any improvement, so I am assuming I must be on the placebo (c). Anyway, after the 12th week there is a washout period of 3 months and hopefully I will then start on the active LFA3TIP for 12 weeks. According to my derm, some patients have reported clearing from this trial. I will keep you informed. Bye for now. -M from Canada


Ed’s Response: Welcome M! Please keep your trial reports coming (we here at FlakeHQ find them fascinating, as you know). Let me check my math...

Your trial involves 24 weeks of treatment with 3 months of no treatment in the middle. So, the whole trial lasts for 9 months (give or take a handful of days)? Here’s what I want to know. What do they let you do to manage your psoriasis during this 9 months? Anything? (Can you use topicals on really flaring lesions, for example?)

An article in the March/April 2000 edition of the NPF Bulletin mentions this experimental drug.  The article title is, "Facing the future of psoriasis treatment" and it begins on page 12.  LFA3TIP is defined as "a fusion protein created to bind with the DC2 receptor, thereby blocking the LFA-3/CD2 connection."  Out of context that's not too enlightening, is it?  Well, it has to do with how the immune system works on a cellular level, and finding drugs that work specifically to correct the immune system anomaly that makes us flake without bothering other immune system functions.  Most of our current drugs work more generally.  In a beautifully lucid passage in the same article, the author writes, "Using cyclosporine, for example, to suppress the immune process of psoriasis is comparable to using a boulder shot from a catapult to knock a can off a fence post."

We look forward to your next report, M. -Ed

This Month's Mail | Archives